Bayesian Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Bayesian Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Buy	+11,900	New	+$113K	0.12%	130
2025 Q2	–	Sell	-17,000	Closed	-$125K	–	776
2025 Q1	$125K	Buy	+17,000	New	+$131K	0.02%	529
2024 Q2	–	Sell	-10,304	Closed	-$93.8K	–	989
2024 Q1	$93.8K	Buy	+10,304	New	+$73.1K	0.01%	718
2023 Q3	–	Sell	-37,400	Closed	-$193K	–	898
2023 Q2	$193K	Buy	+37,400	New	+$222K	0.02%	644
2022 Q3	–	Sell	-16,200	Closed	-$65K	–	929
2022 Q2	$65K	Buy	16,200 +2,200	+16%	+$8.31K	0.01%	708
2022 Q1	$69K	Buy	+14,000	New	+$77.6K	0.01%	717

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bayesian Capital Management's OCUL Position: Q1 2026 in Review

Bayesian Capital Management opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 11,900 shares worth $101K. The stake represents 0.12% of the portfolio and ranks #130 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in OCUL as recently as Q1 2025.

Bayesian Capital Management first reported a position in OCUL in Q1 2022 and has held it in 6 quarters since. The position peaked at $193K in Q2 2023. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Bayesian Capital Management held 11,900 shares of Ocular Therapeutix worth $101K as of Q1 2026.
Ocular Therapeutix was a new Bayesian Capital Management position in Q1 2026.
Ocular Therapeutix made up 0.12% of Bayesian Capital Management's portfolio in Q1 2026, its #130 holding.
Bayesian Capital Management first reported a position in Ocular Therapeutix in Q1 2022 and has held it in 6 quarters since.
Bayesian Capital Management's Ocular Therapeutix position peaked at $193K in Q2 2023.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.